Skip to main content
Premium Trial:

Request an Annual Quote

Five Months after Acquisition, Tepnel Again Downgrades Purchase Price for Orchid Diagnostics

NEW YORK, June 1 (GenomeWeb News) - Tepnel Life Sciences said today that it has revised the final purchase price for its January acquisition of Orchid BioSciences' Orchid Diagnostics unit by more than $1 million.

 

Tepnel said that independent auditors revisited the completed accounts for the acquisition and determined that "a further adjustment of the final purchase price" would be necessary, bringing the final price to $2.49 million in cash. This is a dramatic drop from the $3.5 million purchase price quoted in January, which was itself reduced some $800,000 from a $4.3 million price tag originally proposed in October 2003.

 

Tepnel said that the latest price is the result of $957,531 payable by Orchid Biosciences to Tepnel Life Sciences. Of this, $450,000 is held in escrow, and Tepnel said it expects to receive an additional $507,531 from Orchid Biosciences "directly."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.